KIR2DL3 and HIV infectious disease: The role of the route of HIV exposure in determining whether KIR3DL1/S1 and HLA-Bw4/HLA-F combinations are more potent in parenteral exposures while KIR2DL/HLA-C combinations are more effective at preventing HIV infection by sexual routes of exposure is unclear.